Dr. Butler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney Street
Dana Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-2334Fax+1 617-632-3479
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 2000
Johns Hopkins UniversityResidency, Internal Medicine, 1992 - 1995
Yale School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1995 - 2012
Clinical Trials
- Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma Start of enrollment: 2007 Aug 01
- Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Start of enrollment: 2016 Sep 01
Roles: Contact, Principal Investigator
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. Start of enrollment: 2022 May 02
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 7 citationsKEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.Michele Maio, Matteo S. Carlino, Anthony M. Joshua, Elaine McWhirter, Antoni Ribas
European Journal of Cancer. 2021-11-17 - 85 citationsPhase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2Linh T. Nguyen, Samuel Saibil, Valentin Sotov, Michael X. Le, Leila Khoja
Cancer Immunology, Immunotherapy. 2019-02-11 - 11 citationsFrom Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials WiselyDaphne Day, Arta M. Monjazeb, Elad Sharon, S. Percy Ivy, Eric H. Rubin
Clinical Cancer Research. 2017-09-01
Press Mentions
Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam MethodNovember 14th, 2024- Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal MelanomaJune 8th, 2022
- Asthma Society’s Pollen Tacker Predicts High Pollen Levels This WeekendJuly 14th, 2020
- Join now to see all
Grant Support
- Detection Of Immunogenic Ovarian Cancer AntigensNational Cancer Institute2000–2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
